Biosimilar Threat Looms For J&J, Amgen And Others, Decision Resources Forecasts
J&J and Amgen are the drug makers that will lose the largest percent of cumulative revenues to biosimilars from 2009 to 2019, the research firm estimates.
J&J and Amgen are the drug makers that will lose the largest percent of cumulative revenues to biosimilars from 2009 to 2019, the research firm estimates.